



# REGIONAL PEDIATRIC PARENTERAL DRUG MONOGRAPH

GENERIC NAME

### rocuronium



Effective Date: Dec 2011

CLASSIFICATION

OTHER NAMES

PAGE

Revised Date: Mar9-2016

Neuromuscular

Zemuron

blocking agent

1 of 2

#### ADMINISTRATION POLICY:

IV bolus -

May be administered by a nurse under direct supervision of physician in ED

IV intermittent -

May be administered by a nurse under direct supervision of physician in ED

#### RECONSTITUTION/DILUTION/ADMINISTRATION:

**Available as:** 10 mg/mL – 5 mL vial. REFRIGERATE.

IV bolus: Administer undiluted OR diluted in normal saline over 1 minute. Flush catheter with normal saline after each dose.

**Intermittent:** Administer undiluted OR diluted in normal saline over 2 – 3 minutes. Flush catheter with normal saline after each dose.

Central: No special considerations. Refer to IV bolus.

**DOSAGE:** 

IV bolus: 0.6 - 1.2 mg/kg/doseLoad:

Maintenance: 0.075-0.15 mg/kg/dose every 20-30 minutes to effectIV intermittent:

IV infusion: 4 -- 6 mcg/kg/minute

**Renal impairment:** No dosage adjustment required. No prolongation of effect observed.

**Hepatic impairment:** Load: Use higher end of dosage range (increased volume of distribution)

Maintenance: Usual dosage but increase dosing interval (decreased hepatic clearance)

**Obesity:** Load: Actual body weight

Maintenance: Ideal body weight

**Maximum concentration**: IV bolus: 10 mg/mL

#### STABILITY/COMPATIBILITY:

**Stability of reconstituted vial:** unopened vial -- 90 days at room temperature

opened vial -- 30 days at room temperature

**Stability of final admixture:** 24 hours at room temperature

**Compatibility:** Compatible with D5W, normal saline, Lactated Ringer





# REGIONAL PEDIATRIC PARENTERAL DRUG MONOGRAPH

GENERIC NAME

# rocuronium



Effective Date: Dec 2011	CLASSIFICATION	OTHER NAMES	PAGE
Revised Date: Mar9-2016	Neuromuscular blocking agent	Zemuron	2 of 2

## PRECAUTIONS, POTENTIAL ADVERSE REACTIONS:

- CV: Hypotension, hypertension, arrhythmia, tachycardia
- GI: Vomiting
- Resp: Bronchospasm
- Local: Injection site edema, rash, pruritis
- Other: Hiccoughs, muscle weakness (especially after prolonged infusions)
- Caution in patients with myasthenia gravis or pulmonary disease
- Administration MUST be accompanied by adequate anesthesia or sedation
- Contraindications with hypersensitivity to rocuronium

#### ADDITIONAL NOTES AND NURSING CONSIDERATIONS:

- Onset of action: 1 minute (range: 0.5 3.3 minutes)
- Duration of action: 27 minutes (mean) (range: 17 41 minutes): duration longer in children under 1 year of age
- Required monitoring
  - Cardio-respiratory monitoring required
  - Adequacy of sedation or anesthesia (rocuronium provides no sedative activity)